RaySearch Laboratories AB/Skr RAY B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About RaySearch Laboratories AB
RaySearch Laboratories AB is a medical technology company based in Sweden that specializes in software solutions for radiation therapy used in cancer treatment. The company's primary product is RayStation, an advanced treatment planning system that integrates a comprehensive set of tools for creating radiation therapy plans. Founded in 2000, RaySearch focuses heavily on research and development to innovate in adaptive therapy, automated planning, and machine learning. Its strategic partnerships with major equipment vendors expand its geographic presence, serving clinics and hospitals worldwide. The company's competitive strength lies in its advanced algorithms and focus on improving patient outcomes and treatment workflows.
- Ticker
- Skr RAY B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 464
- Headquarters
- Stockholm, Sweden
- Website
- www.raysearchlabs.com
RAY B Metrics
BasicAdvanced
kr 5.9B
29.40
kr 6.02
-
kr 4.00
2.26%
Price and volume
Market cap
kr 5.9B
52-week high
kr 264.50
52-week low
kr 153.10
Average daily volume
171K
Dividend rate
kr 4.00
Financial strength
Current ratio
1.319
Quick ratio
1.24
Long term debt to equity
0.326
Total debt to equity
0.504
Dividend payout ratio (TTM)
66.98%
Interest coverage (TTM)
25.39%
Profitability
EBITDA (TTM)
343.5
Gross margin (TTM)
89.55%
Net profit margin (TTM)
15.36%
Operating margin (TTM)
23.25%
Effective tax rate (TTM)
22.26%
Revenue per employee (TTM)
kr 2,870,000
Management effectiveness
Return on assets (TTM)
10.29%
Return on equity (TTM)
23.75%
Valuation
Price to earnings (TTM)
29.398
Price to revenue (TTM)
4.516
Price to book
7.31
Price to tangible book (TTM)
26.93
Price to free cash flow (TTM)
31.483
Free cash flow yield (TTM)
3.18%
Free cash flow per share (TTM)
5.622
Dividend yield (TTM)
2.26%
Forward dividend yield
2.26%
Growth
Revenue change (TTM)
3.16%
Earnings per share change (TTM)
-5.74%
3-year revenue growth (CAGR)
10.52%
10-year revenue growth (CAGR)
10.93%
3-year earnings per share growth (CAGR)
47.54%
10-year earnings per share growth (CAGR)
6.65%
10-year dividend per share growth (CAGR)
31.95%
What the Analysts think about RAY B
Analyst ratings (Buy, Hold, Sell) for RaySearch Laboratories AB stock.
Analyst projections of the future price of RaySearch Laboratories AB stock.
Bulls say / Bears say
In Q3, order intake rose 30% and sales reached a record SEK 394 million, with organic growth of 18%. This points to a strong rebound in demand after a weak first half. (MFN.se)
The expanded Accuray partnership includes an USD 8 million RayStation order and joint marketing of adaptive radiotherapy solutions. It gives RaySearch a route to sell its software alongside Accuray’s treatment platforms. (RaySearch Laboratories)
A US clinic has begun treating patients with RayCare and RayStation integrated with Varian TrueBeam. This live reference site could help demonstrate the integrated product to other clinics. (RaySearch Laboratories)
The Q3 rebound has not yet reversed the year-to-date slowdown: nine-month sales fell 1%, while EBIT fell 10% and earnings per share dropped to SEK 4.01 from SEK 4.64. This leaves the broader earnings trend weaker than the latest quarter alone suggests. (MFN.se)
Profitability weakened even as Q3 sales hit a record: EBIT fell 5% and the operating margin narrowed to 21% from 27%. RaySearch attributed pressure to a higher share of hardware sales and increased operating expenses. (MFN.se)
China’s push for domestic healthcare procurement and its demanding regulatory process are a hurdle to RaySearch’s growth there. On its Q2 call, management described the regulatory environment as a strong headwind, despite working with local machine vendors. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
RAY B Financial Performance
Revenues and expenses
RAY B Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RAY B
Fund name | Fund size | Skr RAY B weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 0.05% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.05% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.05% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.